Product Reports Resources Pricing Login Book a demo

Athenex

Biotech & Life Sciences · Buffalo, United States · Founded 2003 · IPO 2017

Athenex is focused on the development and commercialization of therapies for cancer and immunomodulatory diseases

Revenue $103M

Talent graph

Athenex's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

2 investors on Athenex's cap table

Sourced from Dealroom's funding and investor records.

Series A 1 investor entered at this stage
Erie County Industrial Development Agency
Series B+ 1 investor entered at this stage
University of Buffalo

Global footprint

Where Athenex has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States74.4%
🇹🇼 Taiwan8%
🇬🇹 Guatemala6%
🇦🇷 Argentina4%
🇨🇳 China4%
Top 5 of 6 shown

Patent intelligence

Athenex’s patent portfolio

Estimated portfolio value
$83M

37 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Capital deployed

Athenex's 3 investments and acquisitions.

Every disclosed deal where Athenex appeared as a backer or acquirer, 2014–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Athenex's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Athenex's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Athenex

        An AI-synthesized read of the highest-engagement posts about Athenex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Athenex on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.